Palvella Therapeutics
PVLA· Manufacturing· Fiscal year ends in December
CEO pay in FY2025Stock +772.3% in FY2025
Wesley H. Kaupinen is the CEO of Palvella Therapeutics and was paid $3.4M in FY2025 (Dec), down 37%.
Pay$100 in the stock at the end of FY22 → $126
Executives3
See all- 1Wesley H. KaupinenPresident and Chief Executive OfficerFY2025
- 2Kathleen GoinChief Operating OfficerFY2025
- 3Matthew E. KorenbergChief Financial OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allPalvella Therapeutics paid its 3 named executives $7.4M in total in FY2025 (Dec). CEO Wesley H. Kaupinen was paid $3.4M of that.
| Name | |||
|---|---|---|---|
| Wesley H. KaupinenPresident and Chief Executive Officer | |||
| Kathleen GoinChief Operating Officer | |||
| Matthew E. KorenbergChief Financial Officer | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers
No disclosed peer group
No proxy on file names a pay peer group for Palvella Therapeutics. The peer group comes from the proxy statement, so it shows here when a proxy read has it.
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 30, 2026 | FY2025 |
| Annual report | 10-K | Mar 31, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 30, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Proxy statement | DEF 14A | Nov 6, 2024 | FY2023 |
| Annual report | 10-K | Mar 29, 2024 | FY2023 |
